Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Misses Revenue Estimates

Stock Information for Atara Biotherapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Atara Biotherapeutics Inc.

Atara Biotherapeutics Appoints James Huang and Nachi Subramanian to Board of Directors
Atara Biotherapeutics Announces First Quarter Financial Results and Operational Progress
Atara Biotherapeutics Announces Pricing of $16 Million Offering
Atara Biotherapeutics Provides Regulatory Updates on EBVALLO(TM) (tabelecleucel)
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Operational Progress
Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Atara Biotherapeutics, Inc. for potential violations of securities laws
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.